The plasma protease C1-inhibitor treatment market involves the use of plasma-derived and recombinant C1-inhibitor preparations for the treatment of hereditary angioedema (HAE). HAE is a rare genetic condition characterized by attacks of swelling in parts of the body like hands, feet, abdomen, face, airway, and throat. The swelling occurs due to low levels of C1-inhibitor, a blood protein. Plasma protease C1-inhibitor treatment helps control and prevent swelling attacks in patients with HAE. Key products in this market include Cinryze®, Haegarda® and Ruconest®.
The Global plasma protease C1-inhibitor Treatment Market Demand is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the plasma protease C1-inhibitor treatment market are R&D Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. Koninklijke Philips N.V offers Cinryze®, a plasma-derived C1-inhibitor treatment approved for routine prevention and treatment of angioedema attacks in adolescents and adults with HAE.
The plasma protease C1-inhibitor treatment market is driven by the increasing diagnosis of hereditary angioedema and availability of treatment options. Introduction of self-administrable therapies like Haegarda has further fueled the demand for C1-inhibitor treatment. Patients can now effectively manage HAE attacks at home without necessarily waiting for medical assistance.
Advancements in recombinant DNA technology have enabled the development of first-in-class recombinant C1-inhibitor Ruconest approved for the treatment of acute HAE attacks. This has enhanced treatment outcomes while reducing reliance on plasma-derived therapies with limited donor availability.
Market Trends
Increased access to healthcare in developing regions- With growing healthcare spending and improving diagnostic capabilities, more HAE patients are being identified and receive access to C1-inhibitor therapy in developing nations like China, India. This will accelerate the revenue growth of major players in these regions.
Emergence of subcutaneous C1-inhibitor treatments- Major pharmaceutical companies are investing in the development of easy-to-administer subcutaneous C1-inhibitor preparations that can further improve treatment compliance and convenience for patients.
Market Opportunities
Under penetration in developing markets - The availability and affordability of C1-inhibitor therapies remain challenges in developing nations. This presents lucrative market potential as socio-economic conditions improve.
Focus on specialized treatment programs- Establishing HAE specialty centers and patient support initiatives can help undertreated populations gain access to optimized long-term management with C1-inhibitor therapy.
Impact of COVID-19 on Plasma Protease C1-inhibitor Treatment Market Growth
The COVID-19 pandemic has had a significant impact on the plasma protease C1-inhibitor treatment market. During the initial phases of the pandemic, restrictions imposed by various governments globally led to decreased patient visits and deferred non-essential treatments. This negatively impacted the demand for plasma protease C1-inhibitor treatment procedures. However, as the healthcare systems adapted to the new challenges, the market saw a gradual recovery. Telemedicine emerged as an effective tool to ensure continuity of care while maintaining social distancing norms. Manufacturers also focused on ensuring stable supply of essential drugs and therapies despite disruptions in production and supply chains.
Going forward, the demand is expected to steadily grow as deferred treatments are being conducted. However, future waves of infections may again impose restrictions temporarily slowing the market growth. The pharmaceutical companies are continuously working with regulatory authorities to expedite research and development of new drugs and treatments. They are also innovating healthcare delivery models to ensure safety of patients. The governments are supporting these efforts through policy reforms, funding, and infrastructure development initiatives. The long term outlook remains positive driven by increasing awareness, ageing population, and favourable regulatory frameworks.
Geographical Regions with Highest Market Concentration
In terms of value, North America accounts for the largest share of the global plasma protease C1-inhibitor treatment market currently. This is attributed to factors such as rising healthcare expenditure, presence of major market players, and high adoption of advanced treatment options. Within the region, the US holds the dominant position supported by the well-established healthcare infrastructure and favourable reimbursement policies.
Europe is the second largest regional market driven by growing geriatric population base prone to hereditary angioedema and presence of local manufacturers. Presence of key market players and availability of technologically advanced products further supports the market growth in Europe.
Asia Pacific is considered as the fastest growing region for plasma protease C1-inhibitor treatment market globally. This growth can be attributed to increasing spending on healthcare, rising medical tourism, growing incidence of hereditary angioedema, and improving access to diagnosis and treatment in emerging nations.
Get more insights on this topic: Plasma Protease C1-inhibitor Treatment Market
